- ICH GCP
- US Clinical Trials Registry
- Search trials
Search clinical trials for: Olaparib
Total 434 results
-
Memorial Sloan Kettering Cancer CenterCompletedSmall Cell Lung Carcinoma | Small-cell Lung CancerUnited States
-
AstraZenecaMerck Sharp & Dohme LLC; Iqvia Pty LtdCompletedMalignant Solid TumorBelgium
-
CSPC Ouyi Pharmaceutical Co., Ltd.CompletedHealthy ParticipantsChina
-
Dana-Farber Cancer InstituteNovartis; AstraZenecaCompleted
-
AstraZenecaMerck Sharp & Dohme LLC; European Network of Gynaecological Oncological Trial... and other collaboratorsActive, not recruitingRelapsed Ovarian Cancer | Following Complete or Partial Response to Platinum Based Chemotherapy | Platinum Sensitive | BRCA MutatedKorea, Republic of, France, China, Italy, United States, Israel, United Kingdom, Canada, Japan, Germany, Brazil, Netherlands, Belgium, Poland, Australia, Russian Federation, Spain
-
AstraZenecaEuropean Network of Gynaecological Oncological Trial Groups (ENGOT)CompletedEpithelial Ovarian CancerDenmark, France, Germany, Italy, Spain, Poland, Belgium, Canada, United Kingdom, Israel, Norway
-
Nordic Society of Gynaecological Oncology - Clinical...European Network of Gynaecological Oncological Trial Groups (ENGOT); Belgian... and other collaboratorsRecruiting
-
SandozCompletedBreast Cancer | Ovarian CancerIndia
-
National Cancer Institute (NCI)CompletedMalignant Glioma | Recurrent Childhood Ependymoma | Rhabdoid Tumor | Advanced Malignant Solid Neoplasm | Refractory Malignant Solid Neoplasm | Recurrent Hepatoblastoma | Recurrent Langerhans Cell Histiocytosis | Recurrent Malignant Solid Neoplasm | Recurrent Medulloblastoma | Recurrent Neuroblastoma | Recurrent... and other conditionsUnited States, Puerto Rico
-
Qilu Pharmaceutical Co., Ltd.Completed
-
Leiden University Medical CenterUniversity Medical Center Groningen; Erasmus Medical CenterRecruitingBRCA1 Mutation | BRCA2 Mutation | Homologous Recombination Deficiency | Ovarian Neoplasm EpithelialNetherlands
-
AstraZenecaNo longer availablePSR Ovarian Cancer With a BRCA MutationJapan
-
AstraZenecaMerck Sharp & Dohme LLC; Myriad Genetic Laboratories, Inc.CompletedRecurrent Platinum Resistant Ovarian CancerUnited States
-
Duke UniversityAstraZenecaCompletedTriple Negative Breast CancerUnited States
-
Tianjin Medical University Cancer Institute and...RecruitingExtensive-stage Small Cell Lung CancerChina
-
Erasmus Medical CenterRecruitingNeuroendocrine Tumors | Peptide Receptor Radionuclide TherapyNetherlands
-
AstraZenecaCompletedCancer | Advanced Solid MalignanciesJapan
-
Istituti Ospitalieri di CremonaUnknownBreast Cancer | Triple Negative Breast Cancer
-
AstraZenecaCompletedRelapsed Ovarian Cancer, BRCA Mutation, Platinum SensitivityUnited States, Canada
-
AstraZenecaCompleted
-
National Cancer Institute, NaplesRecruitingBRCA Wild Type Platinum Sensitive Recurrent Ovarian CancerItaly
-
National Cancer Institute (NCI)RecruitingLung Neoplasms | Small Cell Lung Cancer | Prostate Cancer | Urothelial Carcinoma | Urothelial CancerUnited States
-
Sheba Medical CenterCompleted
-
AstraZenecaParexelApproved for marketing
-
Azienda Ospedaliero-Universitaria di ModenaRecruitingMetastatic Pancreatic Cancer | Advanced Pancreatic CancerItaly
-
Alexander B Olawaiye, MDAstraZenecaWithdrawn
-
German Breast GroupStemline Therapeutics, Inc.RecruitingBRCA1 Mutation | BRCA2 Mutation | Hormone Receptor Positive HER-2 Negative Breast Cancer | Advanced or Metastatic Breast CancerGermany
-
Brown UniversityAstraZeneca; The Miriam Hospital; Rhode Island HospitalTerminatedProstate Cancer | Adenocarcinoma of the ProstateUnited States
-
National Cancer Institute, NaplesRecruiting
-
AstraZenecaMerck Sharp & Dohme LLC; GOG Foundation; Myriad Genetic Laboratories, Inc.Active, not recruitingAdvanced Ovarian Cancer | Newly Diagnosed | FIGO Stage III-IV | Partial Response | Complete Response | BRCA Mutation | First Line Platinum ChemotherapyKorea, Republic of, France, Italy, United States, Israel, Canada, China, Brazil, United Kingdom, Poland, Australia, Japan, Netherlands, Russian Federation, Spain
-
AstraZenecaCompletedBreast | Prostate | Ovarian | Pancreatic | Advanced TumoursSweden, Spain, Israel, Australia, Germany
-
AZ-VUBAstraZeneca; Kom Op Tegen KankerActive, not recruitingAdvanced Cancers Harbouring Mutations in HRGBelgium
-
AstraZenecaActive, not recruitingRelapsed Ovarian Cancer | Following Complete or Partial Response to Platinum Based Chemotherapy | Platinum SensitiveChina, Malaysia
-
Hospices Civils de LyonCompleted
-
AstraZenecaMyriad Genetic Laboratories, Inc.WithdrawnPlatinum Sensitive Relapsed Ovarian CancerUnited States, Korea, Republic of, Peru, United Kingdom, Philippines
-
Gustave Roussy, Cancer Campus, Grand ParisAstraZenecaRecruiting
-
Royal Marsden NHS Foundation TrustAstraZeneca; Institute of Cancer Research, United KingdomCompleted
-
AstraZenecaCompletedAdvanced Solid TumorsUnited States, Spain
-
Ruijin HospitalUnknownStomach Cancer | Gastric CancerChina
-
AstraZenecaCompletedSolid TumoursBelgium, France, Netherlands, United Kingdom, Denmark
-
Italian Sarcoma GroupAstraZeneca; PharmaMarCompletedAdvanced Soft Tissue SarcomaItaly
-
AstraZenecaActive, not recruitingBreast CancerUnited States, Belgium, Italy, Spain, United Kingdom, Germany, Israel, Austria, Australia
-
AstraZenecaActive, not recruitingMetastatic Triple Negative Breast CancerUnited States, Belgium, Italy, Spain, United Kingdom, Canada, Czechia, Poland, France, Korea, Republic of, Germany, Taiwan, Portugal, Netherlands, Ireland
-
The Netherlands Cancer InstituteCompletedLocally Advanced Malignant Neoplasm | Triple-Negative Invasive Breast Carcinoma | Inflammatory Breast CarcinomaNetherlands
-
University Medical Center GroningenNot yet recruitingHead and Neck Squamous Cell Carcinoma (HNSCC)Netherlands
-
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityNot yet recruiting
-
University of PennsylvaniaAstraZenecaActive, not recruitingHigh Grade Serous CarcinomaUnited States
-
The Netherlands Cancer InstituteCompletedBreast Cancer | Ovarian Cancer | Advanced CancerNetherlands
-
University of Texas Southwestern Medical CenterWithdrawn
-
Gruppo Oncologico del Nord-OvestRecruitingPembrolizumab and Olaparib in Recurrent/Metastatic, Platinum Resistant Nasopharyngeal Cancer (POINT)Nasopharyngeal CarcinomaItaly